Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Equity (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Return on Equity data on record, last reported at 0.23% in Q3 2025.

  • For Q3 2025, Return on Equity fell 405.0% year-over-year to 0.23%; the TTM value through Sep 2025 reached 0.23%, down 405.0%, while the annual FY2024 figure was 1.41%, 114.0% down from the prior year.
  • Return on Equity reached 0.23% in Q3 2025 per FHTX's latest filing, down from 0.56% in the prior quarter.
  • Across five years, Return on Equity topped out at 9.19% in Q1 2023 and bottomed at 8.91% in Q4 2022.
  • Average Return on Equity over 5 years is 0.44%, with a median of 0.56% recorded in 2025.
  • Peak YoY movement for Return on Equity: soared 1044bps in 2023, then tumbled -813bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 1.15% in 2021, then tumbled by -672bps to 8.91% in 2022, then surged by 116bps to 1.46% in 2023, then soared by 60bps to 2.35% in 2024, then tumbled by -90bps to 0.23% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.23% in Q3 2025, 0.56% in Q2 2025, and 1.15% in Q1 2025.